Antimicrobial drug pricing

Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.

Saved in:
Bibliographic Details
Main Authors: Avaneesh Kumar Pandey, Nusrat Shafiq, Ashish Kumar Kakkar, Samir Malhotra, Beth Woods, Christopher Little, Tom Rhodes, Harriet Tuson, Zeshan Riaz, Tom Ashfield, Michael Corley, Ioannis Baltas
Format: Article
Language:English
Published: Nature Portfolio 2024-10-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-024-00594-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846171697666850816
author Avaneesh Kumar Pandey
Nusrat Shafiq
Ashish Kumar Kakkar
Samir Malhotra
Beth Woods
Christopher Little
Tom Rhodes
Harriet Tuson
Zeshan Riaz
Tom Ashfield
Michael Corley
Ioannis Baltas
author_facet Avaneesh Kumar Pandey
Nusrat Shafiq
Ashish Kumar Kakkar
Samir Malhotra
Beth Woods
Christopher Little
Tom Rhodes
Harriet Tuson
Zeshan Riaz
Tom Ashfield
Michael Corley
Ioannis Baltas
author_sort Avaneesh Kumar Pandey
collection DOAJ
description Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.
format Article
id doaj-art-c986fb808f0d49d4877a19b668d7566f
institution Kabale University
issn 2730-664X
language English
publishDate 2024-10-01
publisher Nature Portfolio
record_format Article
series Communications Medicine
spelling doaj-art-c986fb808f0d49d4877a19b668d7566f2024-11-10T12:40:35ZengNature PortfolioCommunications Medicine2730-664X2024-10-01411510.1038/s43856-024-00594-9Antimicrobial drug pricingAvaneesh Kumar Pandey0Nusrat Shafiq1Ashish Kumar Kakkar2Samir Malhotra3Beth Woods4Christopher Little5Tom Rhodes6Harriet Tuson7Zeshan Riaz8Tom Ashfield9Michael Corley10Ioannis Baltas11Department of Pharmacology, Postgraduate Institute of Medical Education and ResearchDepartment of Pharmacology, Postgraduate Institute of Medical Education and ResearchDepartment of Pharmacology, Postgraduate Institute of Medical Education and ResearchDepartment of Pharmacology, Postgraduate Institute of Medical Education and ResearchCentre for Health Economics, University of YorkPfizer UKPfizer UKPfizer UKPfizer UKBritish Society for Antimicrobial ChemotherapyBritish Society for Antimicrobial ChemotherapyInfection, Immunity & Inflammation Department, University College London Institute of Child HealthDespite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.https://doi.org/10.1038/s43856-024-00594-9
spellingShingle Avaneesh Kumar Pandey
Nusrat Shafiq
Ashish Kumar Kakkar
Samir Malhotra
Beth Woods
Christopher Little
Tom Rhodes
Harriet Tuson
Zeshan Riaz
Tom Ashfield
Michael Corley
Ioannis Baltas
Antimicrobial drug pricing
Communications Medicine
title Antimicrobial drug pricing
title_full Antimicrobial drug pricing
title_fullStr Antimicrobial drug pricing
title_full_unstemmed Antimicrobial drug pricing
title_short Antimicrobial drug pricing
title_sort antimicrobial drug pricing
url https://doi.org/10.1038/s43856-024-00594-9
work_keys_str_mv AT avaneeshkumarpandey antimicrobialdrugpricing
AT nusratshafiq antimicrobialdrugpricing
AT ashishkumarkakkar antimicrobialdrugpricing
AT samirmalhotra antimicrobialdrugpricing
AT bethwoods antimicrobialdrugpricing
AT christopherlittle antimicrobialdrugpricing
AT tomrhodes antimicrobialdrugpricing
AT harriettuson antimicrobialdrugpricing
AT zeshanriaz antimicrobialdrugpricing
AT tomashfield antimicrobialdrugpricing
AT michaelcorley antimicrobialdrugpricing
AT ioannisbaltas antimicrobialdrugpricing